Yaws Eradication Funding Diverted, Disease Resurfaces Alongside Pharmaceutical Stock Profit Surges
Yaws, a chronic bacterial infection almost eradicated through global health campaigns, is resurfacing in West Africa and Southeast Asia. The World Health Organization (WHO) had aimed for its elimination by 2020, following massive campaigns in the 1950s that reduced cases by over 95%. However, recent reports from countries like Papua New Guinea, Ghana, and the Solomon Islands indicate a worrying
resurgence, with thousands of new cases appearing annually. This resurgence comes despite continued pledges of international aid for infectious disease control. The Telegraph, reporting on this development, frames it as a 'global health threat' while omitting the long-standing financial mechanisms that often undermine such eradication efforts. Mainstream narratives frequently highlight the
difficulty of reaching remote communities or the challenges of disease surveillance without delving into the actual flow of funds. The initial WHO eradication program in the 1950s was largely successful because it relied on broad, accessible penicillin distribution, a low-cost, effective treatment. The current re-emergence occurs even as major pharmaceutical companies, like Pfizer and Gilead
Sciences, are reporting record profits, particularly from infectious disease portfolios. For example, Pfizer alone reported $100.3 billion in revenue in 2022, a significant portion tied to vaccine and treatment sales, yet funding for a simple, cheap yaws treatment seems to lag. This pattern is not without precedent. In 2014, the US Agency for International Development (USAID) slashed its funding